CLEVELAND--(BUSINESS WIRE)--Human tissues are extensively employed by pharmaceutical and academic researchers to identify and validate new biomarkers and drug discovery targets. Such tissues are also widely used to study the efficacy, reproducibility, and safety of experimental drug candidates against unmet clinical needs.
The Ohio Clinical Trials Collaborative (OCTC) offers drug discovery and development investigators with access to well-annotated human tissue samples for medical research. More than 16,500 frozen samples are stored at the Case Comprehensive Cancer Center’s Tissue Resources Core facility located at University Hospitals Case Medical Center, the primary affiliate of Case Western Reserve University School of Medicine.
“It’s exciting to be working with the Ohio Clinical Trials Collaborative on potential opportunities for business development where we can both provide human tissue samples for research and serve as a central biorepository,” states Robert Wyza, Director of Operations at the Human Tissue Procurement Facility and the Comprehensive Cancer Center Tissue Resources Core.
“This collaboration will open the door to further medical innovation and clinical trial development in Ohio,” adds John R. Peterson, PhD, Global Business Development Director at the OCTC.
With more than 20 years’ experience, the OCTC collects samples in compliance with federal, state, and institutional policies. The OCTC has samples of more than 70 different tissues and organs, featuring customized sample sets by disease, tissue, or organ. Furthermore, the OCTC provides access to world-class translational science researchers.
In addition to these samples, the facility continuously collects samples on a prospective basis at a rate of approximately 6,000 samples per year.
“Providing the global pharma and biotech industry with access to novel human tissue samples is anticipated to speed the discovery and development of new therapeutics for unmet human diseases,” Peterson said.
Fresh samples can be ordered prospectively upon request at the OCTC website at http://ohioclintrials.org/products/human-tissue-samples.
About the Ohio Clinical Trials Collaborative
The OCTC is an initiative under Governor John Kasich’s vision of a premier research medical corridor in Ohio that is co-founded by the Clinical and Translational Science Collaborative at Case Western Reserve University, the Center for Clinical and Translational Science at The Ohio State University and the Center for Clinical and Translational Science and Training at the University of Cincinnati. With offices at Case Western Reserve University’s School of Medicine, the OCTC seeks to establish Ohio as one of the most efficient and effective states in which to test new medications and treatment strategies. The OCTC offers economies of scale and unique capacity, leveraging expertise from across the State of Ohio to conduct clinical trials on behalf of industry sponsors. For more information, please go to www.ohioclintrials.org.
About Case Comprehensive Cancer Center
Case Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center located at Case Western Reserve University. The center, which has been continuously funded since 1987, integrates the cancer research activities of the largest biomedical research and health care institutions in Ohio – Case Western Reserve, University Hospitals (UH) Case Medical Center and the Cleveland Clinic. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. It is led by Stanton Gerson, MD, Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology, who is also the Director of the Seidman Cancer Center at UH Case Medical Center and Director of the National Center for Regenerative Medicine, Case Western Reserve University.
